BioSpace2h
Sana Biotechnology Will Lay Off Employees as It Shifts Pipeline
About a year after cutting staff by 29%, Sana Biotechnology will trim its workforce as it increases investment in its type 1 ...
BioSpace2h
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
BioSpace3h
Lacks Family Lawsuits Seek Share of Profits Stemming from HeLa Cells
A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...
BioSpace3h
FDA Delays Decision on Merus Bispecific Antibody to Review CMC Information
Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...
BioSpace6h
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...
BioSpace6h
Vertex Tops Q3 Forecast on Strength of Cystic Fibrosis Sales, Raises Full-Year Revenue Guidance
Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid ...